CALR and essential thrombocythemia: Thirty-eight patients were classified as ET who had JAK2 V617F mutation, CALR type 1 mutation, CALR type 2 mutation, and no mutation (triple-negative) in 20 (52.6%), 7 (18.4%), 3 (7.9%), and 8 cases (21.1%) respectively (Figure 2).